Viking Therapeutics, Inc.
VKTX
$33.20
-$1.22-3.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 51.67% | 42.50% | 33.11% | 32.36% | 36.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.71% | 50.68% | 49.68% | 45.89% | 54.39% |
| Operating Income | -70.71% | -50.68% | -49.68% | -45.89% | -54.39% |
| Income Before Tax | -77.32% | -36.83% | -28.02% | -22.64% | -30.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.32% | -36.83% | -28.02% | -22.64% | -30.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.32% | -36.83% | -28.02% | -22.64% | -30.58% |
| EBIT | -70.71% | -50.68% | -49.68% | -45.89% | -54.39% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -63.65% | -23.78% | -10.23% | -1.35% | -3.62% |
| Normalized Basic EPS | -63.72% | -23.86% | -10.33% | -1.47% | -3.64% |
| EPS Diluted | -63.65% | -23.78% | -10.23% | -1.35% | -3.62% |
| Normalized Diluted EPS | -63.72% | -23.86% | -10.33% | -1.47% | -3.64% |
| Average Basic Shares Outstanding | 7.93% | 10.55% | 15.63% | 20.04% | 25.17% |
| Average Diluted Shares Outstanding | 7.93% | 10.55% | 15.63% | 20.04% | 25.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |